The litigation centers on allegations that ARS Pharmaceuticals misled investors regarding the timeline for expanded insurance coverage via CVS Caremark. While company leadership previously expressed confidence that coverage would be secured by July 1, 2026, for the summer and back-to-school allergy seasons, those expectations failed to materialize. On June 24, 2026, the company announced that CVS Caremark had deferred its decision until January 2027.

The disclosure triggered an immediate market reaction, with the price of ARS common stock dropping from $10.54 to $8.02 per share in a single day, marking a decline of approximately 23.9%. Investors seeking to act as lead plaintiff must file their applications by October 5, 2026. Robbins LLP, which operates on a contingency fee basis, is managing the case for those who suffered losses during the specified class period.